Publication | Closed Access

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

Treatment And PreventionHuman RetrovirusClinical TrialsAntiviral TherapyHiv-1 InfectionNon-inferiority TrialAntiviral DrugHivMedicineEpidemiologyWeek Results